Abstract
10.1016/j.jaip.2022.01.038Pruritus can be a debilitating symptom for patients with progressive familial intrahepatic cholestasis (PFIC), a disease that commonly presents in young children. In the phase 3 PEDFIC 1 study (NCT03566238), odevixibat, an ileal bile acid transporter inhibitor, reduced pruritus compared with placebo based on caregiver report in children with PFIC using the PRUCISION scale. Patient-reported pruritus data were also collected from patients aged ≥8 years. This analysis examines the correlation between patient- and caregiver-reported pruritus scores in PEDFIC 1.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
